<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Diagnostear Technologies, Inc. — News on 6ix</title>
<link>https://6ix.com/company/diagnostear-technologies-inc</link>
<description>Latest news and press releases for Diagnostear Technologies, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 04 May 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/diagnostear-technologies-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d69cc4beedb30cb6ff3e3a.webp</url>
<title>Diagnostear Technologies, Inc.</title>
<link>https://6ix.com/company/diagnostear-technologies-inc</link>
</image>
<item>
<title>DiagnosTear Technologies Inc. Announces Warrant Extension</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-inc-announces-warrant-extension</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-inc-announces-warrant-extension</guid>
<pubDate>Mon, 04 May 2026 12:30:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") announces that it has extended the expiry date of 5,733,885 outstanding common share purchase warrants (the "November 2024 Warrants") and 133,333 outstanding common share purchase warrants (the "December 2024 Warrants"). The November 2024 Warrants were issued in connection with a non-brokered private placement of subscription receipts and in...</description>
</item>
<item>
<title>DiagnosTear Technologies Inc. Announces Adoption of Semi-Annual Reporting</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-inc-announces-adoption-of-semi-annual-reporting</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-inc-announces-adoption-of-semi-annual-reporting</guid>
<pubDate>Tue, 21 Apr 2026 21:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - April 21, 2026) - DiagnosTear Technologies Inc. ("DiagnosTear" or the "Company") announces that it has adopted a semi-annual financial reporting ("SAR") framework, effective immediately. This change is being made pursuant to British Columbia Securities Commission Coordinated Blanket Order 51-933 Exemptions to Permit Semi-Annual Reporting for Certain Venture Issuers ("CBO 51-933").CBO 51-933 allows eligible venture issuers to voluntarily move from a.</description>
</item>
<item>
<title>DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx(TM) Red Eye</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-announces-regulatory-approvals-in-france-and-study-initiation-with-alyatec-for-tearxtm-red-eye</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-announces-regulatory-approvals-in-france-and-study-initiation-with-alyatec-for-tearxtm-red-eye</guid>
<pubDate>Thu, 26 Feb 2026 22:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, is pleased to announce that it has obtained all required regulatory and ethics approvals to proceed with the clinical study of TeaRx™ Red Eye previously announced in a press release dated December 2, 2025.As previously disclosed, the Company initiated a collaboration with AlyaTec, a.</description>
</item>
<item>
<title>DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-advances-uk-market-entry-through-commercial-collaboration-with-hanson-medical</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-advances-uk-market-entry-through-commercial-collaboration-with-hanson-medical</guid>
<pubDate>Fri, 20 Feb 2026 22:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - February 20, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a developer of rapid point-of-care diagnostics for ophthalmic conditions, today announced that it has entered into a Letter of Intent ("LOI") with Hanson Instruments Ltd. (trading as Hanson Medical), a United Kingdom-based supplier of ophthalmic and optometric equipment, to exclusively explore a commercial partnership for the TeaRx™ dry-eye...</description>
</item>
<item>
<title>DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx(TM) in India</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-signs-letter-of-intent-to-advance-commercial-expansion-of-tearxtm-in-india</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-signs-letter-of-intent-to-advance-commercial-expansion-of-tearxtm-in-india</guid>
<pubDate>Thu, 22 Jan 2026 22:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics, today announced the signing of a Letter of Intent (LOI) with Renovate Biologicals Pvt. Ltd. ("Renovate"), a Hyderabad-based distribution company active in the ophthalmic market, to support the commercial evaluation and potential distribution of TeaRx™ in India.The LOI is part of DiagnosTear's...</description>
</item>
<item>
<title>DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx(TM) Red Eye</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-announces-interim-clinical-results-indicating-high-efficiency-from-tearxtm-red-eye</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-announces-interim-clinical-results-indicating-high-efficiency-from-tearxtm-red-eye</guid>
<pubDate>Sat, 17 Jan 2026 00:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, today announced highly encouraging interim results from its ongoing multi-center Israeli clinical study supporting the development of its TeaRx™ Red Eye diagnostic platform.TeaRx™ Red Eye is being developed as the first rapid, multi-biomarker, point-of-care diagnostic device designed.</description>
</item>
<item>
<title>DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-signs-non-binding-term-sheet-with-sheba-impact-and-ramot-to-exclusively-license-new-eye-imaging-technology-clarify-enabling-needle-free-blood-count</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-signs-non-binding-term-sheet-with-sheba-impact-and-ramot-to-exclusively-license-new-eye-imaging-technology-clarify-enabling-needle-free-blood-count</guid>
<pubDate>Wed, 17 Dec 2025 23:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid eye based diagnostic technologies, is pleased to announce that the Company has signed a non-binding term sheet with Sheba Impact, the Technology Transfer office ("TTO") of Sheba Medical Center ("Sheba MC"), Israel's largest hospital and one of the world's most innovative clinical research institutions, and with Ramot, the TTO.</description>
</item>
<item>
<title>DiagnosTear Technologies Inc. - Confirmation of No Material Change</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-inc-confirmation-of-no-material-change</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-inc-confirmation-of-no-material-change</guid>
<pubDate>Tue, 09 Dec 2025 18:19:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - December 9, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, at the request of CIRO, wishes to confirm that the Company's management is unaware of any material change in the Company's operations that would account for the recent increase in market activity.About DiagnosTear Technologies Inc.DiagnosTear Technologies Inc. is a global leader in...</description>
</item>
<item>
<title>DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx(TM) Red Eye Diagnostic Test</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-announces-clinical-study-with-alyatec-to-advance-analytical-validation-and-fda-submission-pathway-of-tearxtm-red-eye-diagnostic-test</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-announces-clinical-study-with-alyatec-to-advance-analytical-validation-and-fda-submission-pathway-of-tearxtm-red-eye-diagnostic-test</guid>
<pubDate>Tue, 02 Dec 2025 22:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular diagnostics, is pleased to announce a collaboration with AlyaTec, a globally renowned Contract Research Organization (CRO), specializing in allergy and environmental diseases, to initiate a clinical study of TeaRx™ Red Eye in order to advance the global commercialization of TeaRx™ Red Eye and...</description>
</item>
<item>
<title>DiagnosTear Technologies Announces Initiation of a Collaboration with LV Prasad Eye Institute for Advancing the Clinical Validation of TeaRx(TM) Red Eye Diagnostic Test</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-announces-initiation-of-a-collaboration-with-lv-prasad-eye-institute-for-advancing-the-clinical-validation-of-tearxtm-red-eye-diagnostic-test</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-announces-initiation-of-a-collaboration-with-lv-prasad-eye-institute-for-advancing-the-clinical-validation-of-tearxtm-red-eye-diagnostic-test</guid>
<pubDate>Wed, 26 Nov 2025 21:15:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - November 26, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) ("DiagnosTear" or the "Company"), a leader in developing cutting-edge point-of-care eye diagnostic solutions, is pleased to announce its scientific collaboration with the renowned LV Prasad Eye Institute (LVPEI) in Hyderabad, India. The partnership supports the clinical validation of TeaRx™, the Company's next-generation Red Eye diagnostic test.DiagnosTear is currently developing a rapid,</description>
</item>
<item>
<title>DiagnosTear Technologies Inc. Announces Closing of Private Placement of Units</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-inc-announces-closing-of-private-placement-of-units</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-inc-announces-closing-of-private-placement-of-units</guid>
<pubDate>Tue, 18 Nov 2025 13:30:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") Further to its press release from June 3, 2025 and October 24, 2025, the Company is pleased to announce that it has closed its non-brokered private placement of units ("Units") with each Unit consisting of one common share in the capital of the Company (each a "Share") and one common share purchase warrant (each a "Warrant"), in the principal...</description>
</item>
<item>
<title>DiagnosTear Technologies Inc. Announces Upsizing of Private Placement of Units</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-inc-announces-upsizing-of-private-placement-of-units</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-technologies-inc-announces-upsizing-of-private-placement-of-units</guid>
<pubDate>Fri, 24 Oct 2025 12:37:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - October 24, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce, further to its press release from June 3, 2025, its previously announced non-brokered private placement of units ("Units") at a price of $0.50 per Unit has been increased to up to 2,000,000 units for aggregate gross proceeds of $1,000,000 (the "Offering").Each Unit will consist of one common share of the Company (a "Common</description>
</item>
<item>
<title>DiagnosTear Announces Frankfurt Stock Exchange Listing and Corporate Awareness Agreement</title>
<link>https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-announces-frankfurt-stock-exchange-listing-and-corporate-awareness-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/diagnostear-technologies-inc/news/diagnostear-announces-frankfurt-stock-exchange-listing-and-corporate-awareness-agreement</guid>
<pubDate>Wed, 22 Oct 2025 12:35:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce that its common shares are now listed and trading on the Frankfurt Stock Exchange under the trading symbol "X8F." The Company is also pleased to announce it has retained bullVestor Medien GmbH ("bullVestor") to provide certain marketing services for a period of 6 months, commencing on October 21, 2025. This news release is.</description>
</item>
</channel>
</rss>